Skip to Main Content

Paper Details

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Sci Rep
9
2020
Patients, TP53, TP53 hotspot mutant, TP53 mutant, TP53 mutant malignancies, TP53 mutant solid tumors, TP53 mutation, anemia, diarrhea, fatigue, histone deacetylase, ixazomib, metastatic colorectal cancer, nausea, patients, pazopanib, sarcoma, thrombocytopenia, tumor, tumor specimens, vascular endothelial growth factor, vomiting, vorinostat
Author NameAffiliation
Kenneth R HessThe University of Texas MD Anderson Cancer Center
Kenneth R HessThe University of Texas MD Anderson Cancer Center
Scott KopetzThe University of Texas MD Anderson Cancer Center
  • 1 - 3

Datasets

Release 1.2